Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Medtronic plc MDT recently secured the FDA’s approval for the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest ...

Medtronic (NYSE:MDT) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved its heart valve implant, the Evolut FX+ transcatheter aortic valve replacement (TAVR) system ...

Per the latest update, the Evolut FX+ TAVR system is seeing strong uptake in the United States, with international expansion progressing well. With favorable trial results, Medtronic’s ...

Medtronic has released the two-year results from the clinical trial comparing its Evolut system to Edwards Lifesciences’ SAPIEN system. The Evolut system showed significantly less bioprosthetic ...